Incidence, prevalence and disability of spinal cord injury in China from 1990 to 2019: a systematic analysis of the Global Burden of Disease Study 2019

Hu, Shian; Wang, Pengju; Dong, Ying; Li, Feng

doi:10.1007/s00586-022-07441-2

Cited by 12 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The health burden of spinal cord injury (SCI) and ischemic stroke remains high and will likely increase as global populations, including East Asia, continue to age. [1][2][3][4] China, which has one of the largest populations of the world, is expected to have approximately 24%-27% of its population become 65 years old or older by 2050. 5 In addition to the increased risk of SCI from falls 3,6 and stroke 7 associated with advancing age, China is experiencing rapid industrialization and urbanization expansion, which brings higher risk for injury.…”

mentioning

confidence: 99%

“…2 As one of the world's fastest developing nations, China has the largest prevalence of SCI. 2 Stroke is a leading cause of death in China, and like SCI, the prevalence continues to increase. [7][8][9][10][11] Similarly, stroke has historically been the number 1 cause of death among Japanese people; however, due to decreasing mortality rates, it is currently ranked as the fourth most common cause of death.…”

mentioning

confidence: 99%

“…The health burden of spinal cord injury (SCI) and ischemic stroke remains high and will likely increase as global populations, including East Asia, continue to age 1‐4 . China, which has one of the largest populations of the world, is expected to have approximately 24%‐27% of its population become 65 years old or older by 2050 5 .…”

mentioning

confidence: 99%

“…China, which has one of the largest populations of the world, is expected to have approximately 24%‐27% of its population become 65 years old or older by 2050 5 . In addition to the increased risk of SCI from falls 3,6 and stroke 7 associated with advancing age, China is experiencing rapid industrialization and urbanization expansion, which brings higher risk for injury 2 . As one of the world's fastest developing nations, China has the largest prevalence of SCI 2 .…”

mentioning

confidence: 99%

“…In addition to the increased risk of SCI from falls 3,6 and stroke 7 associated with advancing age, China is experiencing rapid industrialization and urbanization expansion, which brings higher risk for injury 2 . As one of the world's fastest developing nations, China has the largest prevalence of SCI 2 . Stroke is a leading cause of death in China, and like SCI, the prevalence continues to increase 7‐11 .…”

mentioning

confidence: 99%

See 4 more Smart Citations

Comparability of Elezanumab Safety, Tolerability, and Pharmacokinetics in Healthy Japanese, Chinese, and White Participants

Kalluri,

Rosebraugh,

Boehm

et al. 2024

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

Elezanumab is a fully human monoclonal antibody, which is directed against repulsive guidance molecule A. The safety, tolerability, pharmacokinetics (PK), and immunogenicity of elezanumab were assessed in 2 Phase 1 clinical studies. The objective of this study was to assess the PK, safety, tolerability, and immunogenicity following intravenous infusion of elezanumab in healthy adult Japanese, Han Chinese, and Caucasian participants as well as Western participants from the single‐ascending‐dose study. Elezanumab exposures were approximately 20% higher in Japanese and Han Chinese participants compared to White participants without controlling for body weight. After statistically controlling for body weight by including it as a covariate, the PK of elezanumab in White participants were comparable to those in Japanese and Han Chinese participants. The clinical implications of these exposure differences are yet to be determined. All adverse events were assessed by the investigator as having no reasonable possibility of being related to the study drugs and were mild in severity. No positive immunogenicity effect was observed that impacted elezanumab exposure or safety.

show abstract